In vivo/ex vivo and behavioural study on central effects of 5-HT1B/1D and 5-HT1A antagonists in guinea pigs

Pharmacology Biochemistry and Behavior

Volumn 88, Issue 3, 2008, Pages 196-204

  Rex, A ^a   Voigt, J P ^b   Wicke, K M ^c   Fink, H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c ABBOTT GMBH AND CO KG   (Germany)

Author keywords

5 HT1A antagonist; 5 HT1B 1D antagonist; Cortex; Forced swim test guinea pig; Hippocampus; Microdialysis; Serotonin; Tissue content

Indexed keywords

N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EX VIVO STUDY; GUINEA PIG; IN VIVO STUDY; NONHUMAN; PREFRONTAL CORTEX; PRIORITY JOURNAL;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN CHEMISTRY; DEPRESSION; FEMALE; GUINEA PIGS; HYDROXYINDOLEACETIC ACID; MICRODIALYSIS; OXADIAZOLES; PIPERAZINES; PYRIDINES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT1D; SEROTONIN; SEROTONIN ANTAGONISTS; SWIMMING;

CAVIA;

EID: 36148979339     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2007.07.016     Document Type: Article

References (50)

1. Adell A., Celada P., and Artigas F. The role of 5-HT1B receptors in the regulation of serotonin cell firing and release in the rat brain. J Neurochem 79 (2001) 172-182
2. Assie M.B., and Koek W. Effects of 5-HT1A receptor antagonists on hippocampal 5-hydroxytryptamine levels: (S)-WAY100135, but not WAY100635, has partial agonist properties. Eur J Pharmacol 304 (1996) 15-21
3. Assie M.B., Ravailhe V., Faucillon V., and Newman-Tancredi A. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther 315 (2005) 265-272
4. Bert B., Fink H., Sohr R., and Rex A. Different effects of diazepam in Fischer rats and two stocks of Wistar rats in tests of anxiety. Pharmacol Biochem Behav 70 (2001) 411-420
5. Bidmon H.J., Schleicher A., Wicke K., Gross G., and Zilles K. Localisation of mRNA for h5-HT1B and h5-HT1D receptors in human dorsal raphe. Naunyn Schmiedebergs Arch Pharmacol 363 (2001) 364-368
6. Carlezon W.A., Pliakas A.M., Parow A.M., Detke M.J., Cohen B.M., and Renshaw P.F. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry 51 (2002) 882-889
7. Cleare A.J., Murray R.M., Sherwood R.A., and O'Keane V. Abnormal 5-HT1D receptor function in major depression: a neuropharmacological challenge study using sumatriptan. Psychol Med 28 (1998) 295-300
8. Davidson C., and Stamford J.A. Evidence that 5-hydroxytryptamine release in rat dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors. Br J Pharmacol 114 (1995) 1107-1109
9. Dawson L.A., Hughes Z.A., Starr K.R., Storey J.D., Bettelini L., Bacchi F., et al. Characterisation of the selective 5-HT1B receptor antagonist SB-616234-A (1-[6-(cis-3,5-dimethylpiperazin-1-yl)-2,3-dihydro-5-methoxyindol-1-yl]-1- [2′-methyl-4′-(5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]methanone hydrochloride): in vivo neurochemical and behavioural evidence of anxiolytic/antidepressant activity. Neuropharmacology 50 (2006) 975-983
10. de Groote L., Klompmakers A.A., Olivier B., and Westenberg H.G. An evaluation of the effect of NAS-181, a new selective 5-HT(1B) receptor antagonist, on extracellular 5-HT levels in rat frontal cortex. Naunyn Schmiedebergs Arch Pharmacol 367 (2003) 89-94
11. Fletcher A., Forster E.A., Bill D.J., Brown G., Cliffe I.A., Hartley J.E., et al. Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent 5-HT1A receptor antagonist. Behav Brain Res 73 (1996) 337-353
12. Gobert A., Dekeyne A., and Millan M.J. The ability of WAY100,635 to potentiate the neurochemical and functional actions of fluoxetine is enhanced by co-administration of SB224,289, but not BRL15572. Neuropharmacology 39 (2000) 1608-1616
13. Hallbus M., Magnusson T., and Magnusson O. Influence of 5-HT1B/1D receptors on dopamine release in the guinea pig nucleus accumbens: a microdialysis study. Neurosci Lett 225 (1997) 57-60
14. Henke J., and Erhardt W. Die Anästhesie beim Nager. In: Erhardt W., Henke J., and Haberstroh J. (Eds). Anästhesie und Analgesie beim Klein- und Heimtier sowie bei Vögeln, Reptilien, Amphibien und Fischen (2004), Schattauer, Stuttgard 642-663
15. Hervas I., Bel N., Fernandez A.G., Palacios J.M., and Artigas F. In vivo control of 5-hydroxytryptamine release by terminal autoreceptors in rat brain areas differentially innervated by the dorsal and median raphe nuclei. Naunyn Schmiedebergs Arch Pharmacol 358 (1998) 315-322
16. Hervas I., Queiroz C.M., Adell A., and Artigas F. Role of uptake inhibition and autoreceptor activation in the control of 5-HT release in the frontal cortex and dorsal hippocampus of the rat. Br J Pharmacol 130 (2000) 160-166
17. Hopwood S.E., and Stamford J.A. Multiple 5-HT(1) autoreceptor subtypes govern serotonin release in dorsal and median raphe nuclei. Neuropharmacology 40 (2001) 508-519
18. Hughes Z.A., and Dawson L.A. Differential autoreceptor control of extracellular 5-HT in guinea pig and rat: species and regional differences. Psychopharmacology (Berl) 172 (2004) 87-93
19. Hughes Z.A., Starr K.R., Scott C.M., Newson M.J., Sharp T., Watson J.M., et al. Simultaneous blockade of 5-HT1A/B receptors and 5-HT transporters results in acute increases in extracellular 5-HT in both rats and guinea pigs: in vivo characterization of the novel 5-HT1A/B receptor antagonist/5-HT transport inhibitor SB-649915-B. Psychopharmacology (Berl) 192 (2007) 121-133
20. Johnson D.A., Gartside S.E., and Ingram C.D. 5-HT1A receptor-mediated autoinhibition does not function at physiological firing rates: evidence from in vitro electrophysiological studies in the rat dorsal raphe nucleus. Neuropharmacology 43 (2002) 959-965
21. Jongsma M.E., Bosker F.J., Cremers T.I., Westerink B.H., and den Boer J.A. The effect of chronic selective serotonin reuptake inhibitor treatment on serotonin 1B receptor sensitivity and HPA axis activity. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 738-744
22. Lemonde S., Du L., Bakish D., Hrdina P., and Albert P.R. Association of the C(- 1019)G 5-HT1A functional promoter polymorphism with antidepressant response. Int J Neuropsychopharmacol 7 (2004) 501-506
23. Liu R.J., Lambe E.K., and Aghajanian G.K. Somatodendritic autoreceptor regulation of serotonergic neurons: dependence on l-tryptophan and tryptophan hydroxylase-activating kinases. Eur J Neurosci 21 (2005) 945-958
24. Millan M.J. Multi-target strategies for the improved treatment of depressive states: conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol Ther 110 (2006) 135-370
25. Mlinar B., Tatini F., Ballini C., Nencioni S., Della Corte L., and Corradetti R. Differential autoinhibition of 5-hydroxytryptamine neurons by 5-hydroxytryptamine in the dorsal raphe nucleus. Neuroreport 16 (2005) 1351-1355
26. Mundey M.K., Fletcher A., and Marsden C.A. Effects of 8-OHDPAT and 5-HT1A antagonists WAY100135 and WAY100635, on guinea-pig behaviour and dorsal raphe 5-HT neurone firing. Br J Pharmacol 117 (1996) 750-756
27. Parsey R.V., Arango V., Olvet D.M., Oquendo M.A., Van Heertum R.L., and John Mann J. Regional heterogeneity of 5-HT1A receptors in human cerebellum as assessed by positron emission tomography. J Cereb Blood Flow Metab 25 (2005) 785-793
28. Parsey R.V., Olvet D.M., Oquendo M.A., Huang Y.Y., Ogden R.T., and Mann J.J. Higher 5-HT(1A) receptor binding potential during a major depressive episode predicts poor treatment response: preliminary data from a naturalistic study. Neuropsychopharmacology 31 (2006) 1745-1749
29. Pineyro G., and Blier P. Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51 (1999) 533-591
30. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., and Carlezon Jr. W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci 21 (2001) 7397-7403
31. Rex A., Fink H., Skingle M., and Marsden C.A. Involvement of 5-HT1D receptors in cortical extracellular 5-HT release in guinea-pigs on exposure to the elevated plus maze. J Psychopharmacol 10 (1996) 219-224
32. Rex A., Voigt J.P., and Fink H. Behavioral and neurochemical differences between Fischer 344 and Harlan-Wistar rats raised identically. Behav Genet 29 (1999) 187-192
33. Rex A., Thomas H., Hortnagl H., Voits M., and Fink H. Behavioural and microdialysis study after neurotoxic lesion of the dorsal raphe nucleus in rats. Pharmacol Biochem Behav 74 (2003) 587-593
34. Roberts C., and Price G.W. Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: an in vitro fast cyclic voltammetry study. Neurosci Lett 300 (2001) 45-48
35. Roberts C., Price G.W., and Jones B.J. The role of 5-HT(1B/1D) receptors in the modulation of 5-hydroxytryptamine levels in the frontal cortex of the conscious guinea pig. Eur J Pharmacol 326 (1997) 23-30
36. Roberts C., Boyd D.F., Middlemiss D.N., and Routledge C. Enhancement of 5-HT1B and 5-HT1D receptor antagonist effects on extracellular 5-HT levels in the guinea-pig brain following concurrent 5-HT1A or 5-HT re-uptake site blockade. Neuropharmacology 38 (1999) 1409-1419
37. Rollema H., Clarke T., Sprouse J.S., and Schulz D.W. Combined administration of a 5-hydroxytryptamine (5-HT)1D antagonist and a 5-HT reuptake inhibitor synergistically increases 5-HT release in guinea pig hypothalamus in vivo. J Neurochem 67 (1996) 2204-2207
38. Ross S.B., and Stenfors C. The forgotten 5-hydroxyindolicacetic acid. J Neurochem 69 (1997) 437-439
39. Rössner W. Stereotaktischer Hirnatlas vom Meerschweinchen (1965), Pallas Verlag, Lochham
40. Schaechter J.D., and Wurtman R.J. Effect of chronic d-fenfluramine administration on rat hypothalamic serotonin levels and release. Life Sci 44 (1989) 265-271
41. Serretti A., Artioli P., Lorenzi C., Pirovano A., Tubazio V., and Zanardi R. The C(- 1019)G polymorphism of the 5-HT1A gene promoter and antidepressant response in mood disorders: preliminary findings. Int J Neuropsychopharmacol 7 (2004) 453-460
42. Skingle M., Sleight A.J., and Feniuk W. Effects of the 5-HT1D receptor antagonist GR127935 on extracellular levels of 5-HT in the guinea-pig frontal cortex as measured by microdialysis. Neuropharmacology 34 (1995) 377-382
43. Stenfors C., Magnusson T., Larsson L.G., Yu H., Hallbus M., Magnusson O., et al. Synergism between 5-HT1B/1D and 5-HT1A receptor antagonists on turnover and release of 5-HT in guinea-pig brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 359 (1999) 110-116
44. Stenfors C., Hallerback T., Larsson L.G., Wallsten C., and Ross S.B. Pharmacology of a novel selective 5-hydroxytryptamine1B receptor antagonist, AR-A000002. Naunyn Schmiedebergs Arch Pharmacol 369 (2004) 330-337
45. Svenningsson P., and Greengard P. p11 (S100A10)-an inducible adaptor protein that modulates neuronal functions. Curr Opin Pharmacol 7 (2007) 27-32
46. Svenningsson P., Chergui K., Rachleff I., Flajolet M., Zhang X., El Yacoubi M., et al. Alterations in 5-HT1B receptor function by p11 in depression-like states. Science 311 (2006) 77-80
47. Tatarczynska E., Klodzinska A., Stachowicz K., and Chojnacka-Wojcik E. Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test. Eur J Pharmacol 487 (2004) 133-142
48. Varnas K., Hurd Y.L., and Hall H. Regional expression of 5-HT1B receptor mRNA in the human brain. Synapse 56 (2005) 21-28
49. Whale R., Clifford E.M., Bhagwagar Z., and Cowen P.J. Decreased sensitivity of 5-HT(1D) receptors in melancholic depression. Br J Psychiatry 178 (2001) 454-457
50. Wicke K, Rex A, Jongen-Relo A, Groth I, Gross G. The guinea pig forced swim test as a new behavioural despair model to characterize potential antidepressants. Psychopharmacology (Berl) in press. doi:10.1007/s00213-007-0874-0.